/AI Therapeutics
Invite

Pending to review

Not sure yet

Interested

Not interested

Get more companies

Download list

Company
Fit assessment
Description
Subspaces
HQ Location
Founded
Employees
Total Funding Raised
Funding Status
Received on
Picks for your space

DeepThink Health leverages machine learning to discover patterns and expand therapeutics, while effectively analyzing genomic data.

DeepThink Health offers an innovative Precision Intelligence Platform that extracts, de-identifies and curates complex clinical, genomic and other contextual health datasets with unmatched accuracy and precision. Our platform transforms unstructured data into actionable intelligence at scale. DeepThink’s solutions then apply advanced analytics and proprietary machine learning to enable a variety of use cases across the healthcare spectrum. Our team has extensive experience and a track record of success in leading healthcare technology companies.
  • Genomic Data Analysis
Richmond (United States)201811 - 50NA
1 year ago

Converger.ai leverages machine learning and data analytics to discover patterns in genetics and expand therapeutic approaches for disease prevention and treatment.

We are a biotechnology company working to unlock the secrets of genetic diversity to improve health. We believe that only with a multi-disciplinary approach, combining the use of computational biology, mathematics and data engineering, can we understand how genetics relates to health. We call this approach data convergence. At converger.ai we are building a platform of data convergence analytical tools creating an evolved understanding of genetics, driving innovations and discoveries to help prevent, diagnose and treat disease.
  • Genomic Data Analysis
Johannesburg (South Africa)20231 - 10$205.13KPre-Seed, $200.00K, June 20, 2023
1 year ago

AliveX effectively utilizes machine learning for pattern discovery and therapeutic expansion, with a strong focus on biomarker identification.

AliveX Biotech is a leading AI + multi-omics technology platform company. Our mission is to accelerate the discovery and effective therapies that improve therapy outcomes worldwide. We facilitate this through leveraging our multi-omics data generation capabilities, proprietary data, AI/ML analytics and knowledge-empowered modeling for a deeper understanding of biological systems.
  • Biomarker Identification
Zürich (Switzerland)201951 - 200Seed, June 22, 2021
1 year ago

BioAI Health effectively utilizes machine learning for pattern discovery and therapeutic expansion, focusing on biomarker identification to enhance personalized medicine.

At BioAI, we are developing world-leading machine learning technology to map the causal biology of disease, develop digital biomarkers, and identify novel drug targets, for the development of better medicine. BioAI’s PredictX Platform intakes your data and generates novel insights. PredictX is capable of ingesting a range of data types including: Digital Pathology, Multiomics, and Real-World Evidence. Using multimodal data and the most advanced AI methodologies, including In-silico phenotype projection and integrated deep learning, we can build predictive and prognostic models across a broad range of therapeutic areas. Founded by a group of friends who started by scribbling their ideas on a piece of paper, today we offer smart, innovative services to dozens of clients worldwide. Our team of experts has a proven track record in developing strategic partnerships with the Pharma industry and solving major challenges in R&D
  • Biomarker Identification
Goffstown (United States)202011 - 50$3.50MSeed, $500.00K, April 9, 2024
1 year ago

Pure Functionals effectively leverages machine learning and genomic data analysis to enhance clinical decision-making and expand therapeutic options.

Developer of a genomic-based artificial intelligence platform designed to offer bespoke health alternatives, as well as provide insight and precision health analysis for benefit of clinical trials. The company's platform offers insights that will be used to initiate clinical trials as well as consult with existing clinical trials in order to improve efficiency and effectiveness, enabling patients to enhance personalized care by improving clinical decision making.
  • Genomic Data Analysis
Amsterdam (Netherlands)20201 - 10Seed, January 1, 2023
1 year ago

Biodesix leverages machine learning and multi-technology approaches to enhance therapeutic options and identify biomarkers, driving personalized medicine in lung cancer diagnostics.

Biodesix is a leading diagnostics solutions company, driven to improve clinical care and outcomes for patients. Biodesix Diagnostic Tests support clinical decisions to expedite personalized care and improve outcomes for patients with lung disease. Biodesix Development Services enable the world’s leading biopharmaceutical, life sciences, and research institutions with scientific, technological, and operational capabilities that fuel the development of diagnostic tests, tools, and therapeutics.   Our culture: The foundation of Biodesix workplace culture is based on these operating principles: TEAM. IMPACT. EXCELLENCE. Based on anonymous team member surveys, Biodesix has been awarded Inc. Magazine's 2024 Best Workplaces and The Denver Post's 2025 Top Workplaces - https://topworkplaces.com/company/biodesix/   #bdsx #biodesix #lungcancer  #biopharma #lifesciences #diagnostics #proteomics #genomics #multiomics #radiomics #medicalAI #liquidbiopsy #digitaldiagnostics #oncology #lungcancer
  • Biomarker Identification
Broomfield (United States)2005201 - 500$445.27MIPO, $72.00M, October 28, 2020
1 year ago

Biotx.ai leverages machine learning for pattern discovery and therapeutic expansion, while also focusing on biomarker identification for precision medicine.

biotx.ai delivers predictive biomarkers as a basis for decision support in precision medicine. We use novel, state of the art, machine learning approaches specifically designed to find complex patterns in biomedical data.
  • Biomarker Identification
Berlin (Germany)201711 - 50Convertible Note, April 5, 2023
1 year ago

INNOPLEXUS effectively leverages machine learning to discover patterns and expand therapeutics, while also focusing on biomarker identification for personalized medicine.

Innoplexus, founded in 2011, leverages Artificial intelligence, machine learning, and blockchain to revolutionize life sciences. With a portfolio of 190+ US/EU patents, it aggregates and analyzes biomedical data to aid drug discovery, optimize clinical trials, and ensure regulatory compliance. By leveraging its ontology, data and AI models, it accelerates drug development and reduces costs. Committed to innovation and collaboration, it empowers Big Pharma and CROs to bring effective treatments to market efficiently and faster. It is headquartered in Eschborn, Germany, with offices in Pune, India, Iselin and San Francisco, USA.
  • Biomarker Identification
Eschborn (Germany)2011201 - 500Series C, April 24, 2019
1 year ago

NashBio effectively leverages machine learning and pattern discovery to advance the development of personalized therapeutics and diagnostics.

At NashBio, we make complex healthcare data easy to use. From idea to execution, we leverage real-world clinical, genomic and imaging data to advance the discovery and development of new therapeutics and diagnostics. A for-profit subsidiary of Vanderbilt University Medical Center, NashBio was launched in 2018 with a mission to harness extensive real-world genomics and other multi-modal datasets, along with powerful bioinformatics tools, to build and deliver a wide range of data products and services that support life science R&D. Our company works with clients in pharma, biotech, diagnostics, medical devices and other life sciences domains to support their most critical R&D use cases. We believe smarter data ultimately enables better outcomes for our clients. Leveraging Vanderbilt University Innovation, NashBio’s hallmarks are deep, high quality, longitudinal datasets that are demographically diverse and clinically relevant, integrated and curated for ease of customer use. In 2023, NashBio launched the Alliance for Genomic Discovery (AGD), in collaboration with Illumina and eight leading pharmaceutical companies, to build one the world’s largest collections of whole genome sequence data linked to de-identified medical records for drug discovery & development. For more information about NashBio, please visit our website.
  • Genomic Data Analysis
Nashville (United States)201811 - 50NA
1 year ago

ATOM leverages machine learning and data-driven modeling to enhance drug discovery, focusing on developing new therapeutics and optimizing the drug design process.

The Accelerating Therapeutics for Opportunities in Medicine (ATOM) consortium is a public-private partnership with the mission accelerating the development of more effective therapies for patients. Our goal is to transform drug discovery from a slow, sequential, and high-failure process into a rapid, integrated, and patient-centric model. We are integrating high performance computing, diverse biological data, and emerging biotechnologies to create a new pre-competitive platform for drug discovery.
  • Drug Discovery Optimization
San Francisco (United States)201711 - 50NA
1 year ago

Cobiomic Bioscience leverages machine learning and bioinformatics to enhance biomarker identification and expand therapeutic options, ultimately improving patient care.

Biotech spin-off of University of Cordoba (EBT-UCO) and IMIBIC. Core lab of Olink providing high-throughput proteomic analysis (biomarkers) using qPCR on 1ul of any biological sample. Boosting personalized medicine in inflammatory and autoimmune diseases.
  • Biomarker Identification
Córdoba (Spain)1 - 10NA
1 year ago

Pharmaeconomica effectively leverages machine learning and AI to discover new drug candidates, adapt to various therapeutic areas, and optimize the drug discovery process.

Pharmaeconomica, headquartered in Belgium, pioneers AI-driven small-molecule drug discovery. Our innovative approach integrates cutting-edge AI technology, revolutionizing traditional processes to accelerate steps, enhance efficiency, and slash costs associated with experiments. By minimizing the need for physical experiments, our AI-driven platform optimizes discovery tasks like molecule design and testing, ensuring effective validation of results. Innovating Drug Discovery with Pharmaeconomica At Pharmaeconomica, we're at the forefront of drug discovery innovation. With a seasoned team, we prioritize solutions for therapeutic areas with high unmet medical needs, driving groundbreaking advancements in the field. Revolutionary ML Platform for Identifying AD Inhibitors Powered by machine learning, our proprietary platform swiftly analyzes extensive datasets, uncovering novel drug candidates with unrivaled efficiency. Focused on Alzheimer's disease, we're committed to identifying inhibitors that target its complex nature, aiming to enhance patient outcomes significantly. Empirical Evidence and Theoretical Models Supporting Our Platform Our platform shows promising results, surpassing traditional methods in identifying potential AD inhibitors. Computational models forecast substantial reductions in key markers of Alzheimer's progression, underlining our platform's potential impact. Beyond Alzheimer's: A Versatile Platform for Drug Discovery While Alzheimer's remains our initial focus, our adaptable platform enables swift adaptation to other disease targets. Continuously enhancing our capabilities, we actively seek partnerships to propel the future of personalized medicine.
  • Drug Discovery Optimization
Oostende (Belgium)20121 - 10NA
1 year ago

Owkin effectively utilizes machine learning to discover patterns, expand therapeutics, and identify biomarkers, enhancing personalized medicine.

Owkin is building the first BASI to unlock breakthroughs in therapies, diagnostics, and rejuvenation, while reshaping how humanity understands and engineers biology. Like other frontier AI companies, we believe the leap from narrow tools to true reasoning systems marks the start of a new era — where intelligence is not just assisting scientists but autonomously advancing discovery. Owkin’s moats are structural and compounding. We are creating the only large-scale reasoning model trained natively on patient-level multimodal data and reinforced through real biological feedback — a closed-loop system that continuously improves itself. Exclusive partnerships with world-class hospitals, unique longitudinal datasets, and automated lab infrastructure create a defensibility flywheel similar to the data moats seen in other generational AI companies. By uniting reasoning models, agentic workflows, and living biological systems, Owkin is building the operating system for biology — a platform no one else can replicate, and the inevitable leader in general-purpose biology intelligence.
  • Biomarker Identification
New York (United States)2016201 - 500$304.10MSeries B, $50.00M, June 8, 2022
1 year ago

Frontier Medicines effectively leverages machine learning to discover new patterns in protein interactions and expand therapeutic options, optimizing the drug discovery process.

Frontier Medicines, located in South San Francisco, CA and Boston, MA, is a precision medicine company that has pioneered a powerful discovery and development platform designed to generate medicines against disease-causing proteins previously considered undruggable. We are deploying our technologies in chemoproteomics, covalent drug discovery, and machine learning to develop a pipeline of groundbreaking medicines against the most important drivers of disease. Our lead program targets both the activated and inactive forms of KRAS G12C, a validated driver in a number of cancers that until recently has been undruggable. Our pipeline embodies our vision of bolding advancing science to defeat disease, starting with cancer.
  • Drug Discovery Optimization
San Francisco (United States)201851 - 200$255.50MSeries C, $20.00M, June 25, 2024
1 year ago

Vium leverages machine learning to discover patterns and identify biomarkers, facilitating the advancement of new therapeutics in preclinical research.

Provider of digital biomarkers intended to assist in pre-clinical drug research. The company's biomarkers are derived from artificial intelligence, machine learning and sensor technology and assists in accelerating the pre-clinical drug discovery and development pipeline, enabling researchers and drug developers to obtain improved insights into disease progression and take better decisions on which compounds should be advanced to the clinic.
  • Biomarker Identification
San Mateo (United States)201351 - 200$53.94MAcquired, July 2020
1 year ago

The USC Big Data Health Science Center leverages machine learning for innovative research, discovering patterns and expanding therapeutic approaches, while also focusing on biomarker identification.

The University of South Carolina (USC) Big Data Health Science Center (BDHSC), an interdisciplinary enterprise and one of the USC Excellence Initiatives established in 2019, promotes and supports big data health science research through capacity development, academic training, professional development, community engagement, and methodological advancement. Its five content cores (Artificial Intelligence for Sensing and Diagnosis, Electronic Health Records, Genomics, Geospatial, and Social Media) and two functional hubs (Business/Entrepreneurship and Technology) embody interdisciplinary collaboration and foster cutting-edge research and discovery. Our mission is to be an innovation-driven enterprise that can facilitate and accelerate a sustained, high-caliber transformation of the USC into a global leader in big data health science.
  • Biomarker Identification
United States11 - 50NA
1 year ago

Bioada leverages machine learning for pattern discovery and aims to expand therapeutics through innovative biomarker and drug discovery solutions.

At Bioada, we redefine the future of healthcare by empowering early disease detection and personalized treatments. Our AI-powered multi-omics platform is the only solution in the world that seamlessly integrates all types of omics data, solving the biomarker reproducibility challenge and unlocking new possibilities in biomarker and therapeutic discovery. From identifying life-changing diagnostic biomarkers to targeting novel therapeutic drivers, Bioada’s proprietary Genomarker platform and cutting-edge research methodologies set a new standard in accuracy, speed, and reliability. Our robust pipeline addresses diverse disease areas, including oncology, neurology, and rare diseases, with diagnostics achieving unprecedented precision and therapeutics aimed at uncovering new frontiers in treatment. Driven by our mission to put patients first, we bridge the gap between cutting-edge science and compassionate care, transforming innovation into real-world solutions.
  • Biomarker Identification
Toronto (Canada)20211 - 10NA
1 year ago

Intelligent OMICS leverages machine learning to discover patterns and expand therapeutic options, while also identifying biomarkers for personalized medicine.

Intelligent OMICS Ltd (Intellomx) is a UK-based AI company that discovers new drugs. We use proprietary technology to identify the biological targets that research has missed and we then progress drug development from idea to IND. We collaborate with others via fee-for-service projects but we also practice what we preach, applying our own technology in-house. We currently seek partners for our lung cancer/KRAS drugs, identified using our own technology. Contact us if we can help you discover drugs for your pipeline too. Technology: Our systems approach is called "Intuitive Informed Intelligence". Our technology approach is based on high speed creation of Artificial Neural Networks (ANNs) which can evaluate tens of millions of data in short period of time, to identity key drivers for systems biology. And to connect these drives to therapeutic modalities including new drugs, repurposed drugs and biomarker panels for disease. Intellomx uses novel proprietary Artificial Intelligence approaches applied to translational biology to discover new drugs for old diseases identify existing drugs for new targets create new diagnostics to stratify patient populations We transform biological data into clinical benefit! Come join the AI-driven drug discovery revolution.
  • Biomarker Identification
Nottingham (United Kingdom)20091 - 10NA
1 year ago

OntoChem leverages machine learning and pattern discovery to enhance therapeutic development and identify biomarkers, showcasing their innovative approach in the life sciences.

No more data siloes. No more missed connections. Advanced chemical search and analysis made accessible to all. Unlock and extract insight for life sciences and chemistry. OntoChem enables your teams to consolidate and normalize all internal and external data from knowledge scattered across different documents, systems and geographical locations. OntoChem is part of Digital Science. Visit our website at ontochem.com
  • Biomarker Identification
Halle (Germany)201511 - 50Acquired, June 2023
1 year ago

Pheiron leverages machine learning to discover patterns and develop targeted therapeutics, while also focusing on biomarker identification for personalized medicine.

We radically improve the probability of success in drug development by getting right what really matters: human evidence to back the target and prognostic disease signatures to define the population.
  • Biomarker Identification
Berlin (Germany)20231 - 10$4.22MVenture - Series Unknown, $4.22M, June 20, 2025
1 year ago

IMVARIA leverages machine learning to enhance patient outcomes through novel pattern discovery and the expansion of therapeutics, focusing on digital biomarker identification.

IMVARIA is advancing noninvasive AI biomarkers for better patient lives. We bring artificial intelligence to imaging and lab data, re-imagining clinical assessments in serious diseases. IMVARIA serves Fibresolve -- the first AI diagnostic tool in interstitial lung disease (ILD) and idiopathic pulmonary fibrosis (IPF). Fibresolve is an FDA Breakthrough Device and is authorized by the FDA to serve as an adjunctive, non-invasive diagnostic tool for patients with suspected ILD and IPF. Beyond ILD and IPF, IMVARIA is developing AI biomarkers in multiple areas including oncology, pulmonology, immunology, and more.
  • Biomarker Identification
Berkeley (United States)201911 - 50Venture - Series Unknown, January 7, 2026
1 year ago

The company effectively leverages machine learning for biomarker discovery and therapeutic expansion, demonstrating a strong fit in the healthcare innovation space.

Promise Bio is using broad epiproteomics and AI to advance precision medicine for chronic diseases. Our platform provides comprehensive post-translational modification (PTM) profiling enhanced with clinical and functional context, delivering insights for precise, data-driven decisions. We partner with leading research organizations and pharmaceutical companies to discover novel biomarkers, treatment selection tools, and drug targets.
  • Biomarker Identification
Tel Aviv (Israel)202311 - 50$8.30MGrant, December 16, 2024
1 year ago

Talon Biomarkers leverages machine learning for data analysis, discovers patterns in immune cell responses, and enhances therapeutic strategies through biomarker identification.

Talon Biomarkers is a biomarker discovery engine built to capture indicators of disease and therapy from a sea of immune cells. We're fueled by a uniquely powerful and robust technology platform that changes the old-school paradigm of how a contract-research organization works. Talon NEST : Expert cell processing. Your samples handled with care, stored safely locally and ready for downstream assays. Talon SURVEY : High-parameter flow cytometry. 20+ color flow cytometry strikes the perfect balance between high information content and practicality. Talon's founder has led the field, developing widely used instrumentation, reagents, and informatics. Why trust your samples with pretenders, instead of the world's experts? Talon DEEP-DIVE : Molecular cytometry. Profile your sample in the deepest way possible, by analyzing 100+ proteins and the whole transcriptome, cell-by-cell. Talon's founder helped develop and optimize this technology. We bring rigor to this exciting technology. Talon CAPTURE : Powerful and interpretable informatics. Ditch the black-box, proprietary, artificial intelligence algorithms. We offer fast, easy-to-explain, complete, and comprehensive data analysis, built to precisely identify the cell types driving patient differences. We are your partners in science, helping with experimental and study design, data acquisition, analysis, and even interpretation of results. We have strategic partnerships with influential and cutting-edge companies in the single cell, immuno-oncology, and immunoassay spaces, coupled with the expertise and creativity to realize your study goals! Reach out to learn more!
  • Biomarker Identification
Whippany (United States)20211 - 10$75.00KGrant, $75.00K, October 15, 2024
1 year ago

The company effectively leverages machine learning for glycopeptide analysis, enabling pattern discovery and expanding therapeutics while focusing on biomarker identification.

CellKey develops an LC/MS-derived analytic pipeline (SpAC9) that enables proprietary AI/ML-based glycoprotein analysis with enhanced accuracy and reduced time & cost.
  • Biomarker Identification
Cheongju (South Korea)201911 - 50Seed, February 28, 2022
1 year ago

Ariana Pharma effectively leverages machine learning and advanced analytics to discover patterns, expand therapeutics, and identify biomarkers, enhancing drug development processes.

Ariana Pharma is a leading Artificial Intelligence (AI) drug development company. Using its KEM® Artificial Intelligence (xAI) technology, Ariana helps its partners introduce personalized medicine clinical trial design into their protocols and optimize clinical endpoints, identify biomarkers of therapeutic response and potential synergistic therapies. Ariana routinely collects and combines clinical data with omic data, immunological readouts (such as Fluorescence-Activated Cell Sorting (FACS)), microbiota, Patient Reported Outcomes (PRO) as well as Real World Evidence (RWE) data. Combining advanced data analytics, drug development, and regulatory expertise, Ariana helps translate findings into innovative clinical development plans and regulatory approvals. With a growing number of successful therapeutic development programs, KEM® is an FDA-assessed technology that systematically explores combinations of biomarkers, producing more effective biomarker signatures for precision medicine. Ariana has developed Onco KEM®, the most advanced, clinically tested, oncology therapeutic decision support system. Founded in 2003 as a spin-off of the Institut Pasteur, Paris, France, the company operates a subsidiary in the United States since 2012.
  • Biomarker Identification
Paris (France)200311 - 50$2.30MSeries A, $2.30M, July 9, 2008
1 year ago